Los Angeles, CA – The Law Offices of Frank R. Cruz announces an investigation of BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) on behalf of investors concerning the Company’s possible violations of federal securities laws.

On or about September, 2024, BioAge conducted its IPO, selling 12.65 million shares of stock for $18 per share.

Then, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag.

On this news, BioAge’s stock price declined $15.44 or 76.85% per share, to close at $4.65 per share on December 9, 2024.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased BioAge securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com.  If you inquire by email please include your mailing address, telephone number, and number of shares purchased.